Latest News Releases From The Newsroom
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Intellia Therapeutics and Ocular Therapeutix: Promising Trial Data for HAE and Wet AMD
June 11th, 2023
Intellia Therapeutics, Inc. (Nasdaq: NTLA) has shared updated interim results from the Phase 1 portion of their ongoing study of NTLA-2002, a CRISPR candidate for treating hereditary angioedema (HAE). The company believes that the data reinf. Read more
Quarterly Results Ahead: Adobe, Kroger, Jabil, and Cognyte Reports Coming
June 10th, 2023
Thursday, June 15, will see several companies releasing their financial results, including: Adobe Inc. (Nasdaq: ADBE), a global leader in digital media and marketing solutions, is set to announce its second-quarter fiscal year 2023 results after t. Read more
Earnings Figures Preview: Lennar, Anterix, Aurora Cannabis, and High Tide
June 10th, 2023
Several companies are expected to report their financial results on Wednesday, June 14, including: Lennar Corporation (NYSE: LEN)(NYSE:LEN.B), a leading home construction and real estate development company, is set to announce its second-qua. Read more
Biogen: FDA Panel Backs OK of Alzheimer's Drug; Disc Medicine: Upgraded, Promising Trial Data
June 10th, 2023
Eisai and Biogen's (Nasdaq: BIIB) Alzheimer's drug candidate, LEQEMBI (lecanemab-irmb), received unanimous support from FDA PCNS panel based on Phase 3 Clarity AD trial data. The committee acknowledged its clinical benefit, overall benefit-r. Read more
GE Awarded up to $422.81M Contract; Primerica, CRISPR, Cineverse and Corning: PT Hiked
June 10th, 2023
General Electric Company's (NYSE: GE) subsidiary, GE Aerospace, has secured a significant contract from the Defense Logistics Agency Aviation for supplies related to the F-series engines (F101/110/118). The firm-fixed price, requirements-typ. Read more
23andMe: Strategic Move; Oracle, Tesla and Microsoft: PT Boost Hint at Potential Upsides
June 09th, 2023
23andMe Holding Co. (Nasdaq: ME), a leading genetic testing and personal genomics company, has disclosed in a regulatory filing with the SEC a reduction in force involving around 75 employees, representing approximately 9% of its workforce. . Read more
Pfizer to End License Deal with Theravance Bio; Truist Bullish On Vail Resorts and Leonardo DRS
June 09th, 2023
Theravance Biopharma Ireland Limited, an affiliate of Theravance Biopharma, Inc. (Nasdaq: TBPH), entered into a global license agreement with Pfizer Inc. (NYSE: PFE) in December 2019 for its preclinical skin-selective, locally acting pan-JAK inhibito. Read more
Aehr Test Systems Gets $13.7M in Orders; Fisker Targets Chinese Market
June 09th, 2023
Aehr Test Systems (Nasdaq: AEHR) has secured significant orders worth $13.7 million from a leading Fortune 500 semiconductor device supplier, who is a major player in the automotive semiconductor market. The orders are for Aehr's WaferPak fu. Read more
Vertex Pharma, CRISPR Surge On Exa-cel Trials Data; Sonoma Pharma Soars on Pulse Lavage Irrigation Solution
June 09th, 2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics AG (Nasdaq: CRSP) have announced positive results from pivotal trials for their investigational treatment, exagamglogene autotemcel (exa-cel), in patients with transfusion-dep. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login